With Cannabis Investment, Constellation Bets on the Big Unknown

(Bloomberg) -- Constellation Brands Inc. isn’t quite sure whether legal cannabis is friend or foe to the alcohol industry. Either way, it wants in. 

The maker of Robert Mondavi wine, Corona beer and Svedka vodka is still waiting for the chips to fall into place after entering the up-and-coming (and turbulent) marijuana industry last year by taking a minority stake in Canada’s Canopy Growth. The rapid increase of the cannabis market has caused analysts to question whether drinkers could shift their spending to smoking as prohibitions on the plant’s recreational use are removed.

“It’s probably not worth getting in a big debate right now about whether it’s cannibalistic or complementary,” Constellation Chief Executive Rob Sands said on a call with analysts Friday. “There’s just not enough information to really say how that’s going to affect beverage alcohol generally moving forward. What we do know is it’s going to be a big market worldwide.”

The Victor, New York-based company’s cannabis investment is being closely watched since it’s the first time that big alcohol has entered the so-called Green Rush. The scrutiny only intensified this week after U.S. Attorney General Jeff Sessions rescinded the Obama-era policy that let federal prosecutors look the other way while states set up their own markets for marijuana. The announcement followed California’s launch of a legal marketplace on Jan. 1.

For now, Sands says Constellation and Canopy are developing a nonalcoholic cannabis beverage for release when Canada’s government legalizes pot drinks, expected in 2019.

Constellation could certainly use a new growth source. Its sales of wine and spirits have persistently fallen, and investors are starting to notice. 

Shares of the company fell as much as 4.2 percent to $216.25 on Friday, the most intraday in more than 10 months, after it reported declines in volume and sales for wine and spirits. Constellation has ridden the strength of its imported Mexican beer to become an investor darling -- 15 analysts recommend buying the shares and none recommend selling them -- but even growth in that category was less than what some had expected. 

To contact the reporter on this story: Jennifer Kaplan in Los Angeles at jkaplan84@bloomberg.net.

To contact the editors responsible for this story: Nick Turner at nturner7@bloomberg.net, Jonathan Roeder, Lisa Wolfson

©2018 Bloomberg L.P.